C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

J. Tabernero,E. Elez Fernandez,F. Ghiringhelli,G. Folprecht,G. Curigliano,S. Siena,C. Cremolini, A. Sobrero, M. Kwiatek, S. Rosello Keranen,D. Ahn, C. Punt,D. Laurent, M. Ferrara, A. Pellacani,A. Capriati

Annals of Oncology(2020)

引用 3|浏览69
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要